{"pmid":32209887,"title":"Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment.","text":["Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment.","Chin Med J (Engl)","Lin, John","Ouyang, Jing","Peng, Xiao-Rong","Isnard, Stephane","Fombuena, Brandon","Routy, Jean-Pierre","Chen, Yao-Kai","32209887"],"journal":"Chin Med J (Engl)","authors":["Lin, John","Ouyang, Jing","Peng, Xiao-Rong","Isnard, Stephane","Fombuena, Brandon","Routy, Jean-Pierre","Chen, Yao-Kai"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209887","week":"202013|Mar 23 - Mar 29","doi":"10.1097/CM9.0000000000000816","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662444220190818304,"score":7.208847,"similar":[{"pmid":32022370,"title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","text":["Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.","Chembiochem","Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray","32022370"],"abstract":["With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics."],"journal":"Chembiochem","authors":["Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32022370","week":"20206|Feb 03 - Feb 09","doi":"10.1002/cbic.202000047","keywords":["*2019-nCoV","*3CLpro","*RdRp","*SARS","*antiviral agents","*coronavirus","*spike proteins"],"source":"PubMed","locations":["ACE2-based"],"topics":["Treatment"],"weight":1,"_version_":1662334544608493570,"score":51.43828},{"pmid":32127666,"title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","text":["Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","Nat Rev Drug Discov","Li, Guangdi","De Clercq, Erik","32127666"],"journal":"Nat Rev Drug Discov","authors":["Li, Guangdi","De Clercq, Erik"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32127666","week":"202010|Mar 02 - Mar 08","doi":"10.1038/d41573-020-00016-0","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1662334544030728192,"score":45.299446},{"pmid":32145386,"title":"Remdesivir as a possible therapeutic option for the COVID-19.","text":["Remdesivir as a possible therapeutic option for the COVID-19.","Travel Med Infect Dis","Al-Tawfiq, Jaffar A","Al-Homoud, Ali H","Memish, Ziad A","32145386"],"journal":"Travel Med Infect Dis","authors":["Al-Tawfiq, Jaffar A","Al-Homoud, Ali H","Memish, Ziad A"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32145386","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.tmaid.2020.101615","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543919579137,"score":43.565758},{"pmid":32201439,"pmcid":"PMC7074432","title":"Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.","text":["Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.","Indian J Pharmacol","Sarma, Phulen","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Medhi, Bikash","32201439"],"journal":"Indian J Pharmacol","authors":["Sarma, Phulen","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Medhi, Bikash"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201439","week":"202013|Mar 23 - Mar 29","doi":"10.4103/ijp.IJP_119_20","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543335522305,"score":43.38267},{"pmid":31996494,"title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV).","text":["Drug treatment options for the 2019-new coronavirus (2019-nCoV).","As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.","Biosci Trends","Lu, Hongzhou","31996494"],"abstract":["As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments."],"journal":"Biosci Trends","authors":["Lu, Hongzhou"],"date":"2020-01-31T11:00:00Z","year":2020,"_id":"31996494","week":"20205|Jan 27 - Feb 02","doi":"10.5582/bst.2020.01020","keywords":["2019-nCoV","Coronaviruses","pneumonia"],"source":"PubMed","locations":["China","Chinese","Capsules"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662334544669310976,"score":42.533398}]}